Literature DB >> 12454652

Better therapeutics through microarrays.

David L Gerhold1, Roderick V Jensen, Steven R Gullans.   

Abstract

DNA microarrays are an integral part of the process for therapeutic discovery, optimization and clinical validation. At an early stage, investigators use arrays to prioritize a few genes as potential therapeutic targets on the basis of various criteria. Subsequently, gene expression analysis assists in drug discovery and toxicology by eliminating poor compounds and optimizing the selection of promising leads. Integral to this process is the use of sophisticated statistics, mathematics and bioinformatics to define statistically valid observations and to deduce complex patterns of phenotypes and biological pathways. In short, microarrays are redefining the drug discovery process by providing greater knowledge at each step and by illuminating the complex workings of biological systems.

Mesh:

Substances:

Year:  2002        PMID: 12454652     DOI: 10.1038/ng1042

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  27 in total

1.  Multiplex mRNA assay using electrophoretic tags for high-throughput gene expression analysis.

Authors:  Huan Tian; Liching Cao; Yuping Tan; Stephen Williams; Lili Chen; Tracy Matray; Ahmed Chenna; Sean Moore; Vincent Hernandez; Vivian Xiao; Mengxiang Tang; Sharat Singh
Journal:  Nucleic Acids Res       Date:  2004-09-08       Impact factor: 16.971

2.  VeloceGenomics: an accelerated in vivo drug discovery approach to rapidly predict the biologic, drug-like activity of compounds, proteins, or genes.

Authors:  Ruben Papoian; Andreas Scherer; Muriel Saulnier; Frank Staedtler; André Cordier; Francois Legay; Gerard Maurer; Joerg Staeheli; Jacky Vonderscher; Salah-Dine Chibout
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

3.  Semiautomated multiplexed quantum dot-based in situ hybridization and spectral deconvolution.

Authors:  Richard J Byers; Dolores Di Vizio; Fionnuala O'connell; Eleni Tholouli; Richard M Levenson; Kirk Gossage; Kirk Gossard; David Twomey; Yu Yang; Elisa Benedettini; Joshua Rose; Keith L Ligon; Stephen P Finn; Todd R Golub; Massimo Loda
Journal:  J Mol Diagn       Date:  2007-02       Impact factor: 5.568

Review 4.  Mechanisms of drug combinations: interaction and network perspectives.

Authors:  Jia Jia; Feng Zhu; Xiaohua Ma; Zhiwei Cao; Zhiwei W Cao; Yixue Li; Yixue X Li; Yu Zong Chen
Journal:  Nat Rev Drug Discov       Date:  2009-02       Impact factor: 84.694

5.  Analysis of the gene expression profile of curcumin-treated kidney on endotoxin-induced renal inflammation.

Authors:  Fang Zhong; Hui Chen; Yuanmeng Jin; Shanmai Guo; Weiming Wang; Nan Chen
Journal:  Inflammation       Date:  2013-02       Impact factor: 4.092

6.  Gene expression reveals overlap between normal aging and Alzheimer's disease genes.

Authors:  Dimitrios Avramopoulos; Megan Szymanski; Ruihua Wang; Susan Bassett
Journal:  Neurobiol Aging       Date:  2010-06-08       Impact factor: 4.673

7.  Identifying inhibitors of epithelial-mesenchymal transition by connectivity map-based systems approach.

Authors:  Ajaya Kumar Reka; Rork Kuick; Himabindu Kurapati; Theodore J Standiford; Gilbert S Omenn; Venkateshwar G Keshamouni
Journal:  J Thorac Oncol       Date:  2011-11       Impact factor: 15.609

8.  Using patient DNA to optimize therapy in heart failure patients: a move toward perfection.

Authors:  Howard L McLeod
Journal:  Heart Fail Rev       Date:  2010-05       Impact factor: 4.214

9.  ATF3 protects against renal ischemia-reperfusion injury.

Authors:  Takumi Yoshida; Hidekazu Sugiura; Michihiro Mitobe; Ken Tsuchiya; Satsuki Shirota; Sayoko Nishimura; Shunji Shiohira; Hiroshi Ito; Kiyoshi Nobori; Steven R Gullans; Takashi Akiba; Kosaku Nitta
Journal:  J Am Soc Nephrol       Date:  2008-01-30       Impact factor: 10.121

10.  Balancing false positives and false negatives for the detection of differential expression in malignancies.

Authors:  F De Smet; Y Moreau; K Engelen; D Timmerman; I Vergote; B De Moor
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.